Opus Point Partners Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Opus Point Partners Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-18,000	Closed	-$175K	–	45
2018 Q3	$175K	Sell	18,000 -2,000	-10%	-$20.2K	0.42%	44
2018 Q2	$204K	Hold	20,000	–	–	0.44%	46
2018 Q1	$260K	Sell	20,000 -20,000	-50%	-$298K	0.51%	45
2017 Q4	$716K	Hold	40,000	–	–	0.62%	39
2017 Q3	$1M	Hold	40,000	–	–	0.9%	34
2017 Q2	$964K	Sell	40,000 -40,000	-50%	-$884K	0.88%	37
2017 Q1	$1.54M	Hold	80,000	–	–	1.14%	30
2016 Q4	$1.23M	Hold	80,000	–	–	0.98%	31
2016 Q3	$1.04M	Buy	80,000 +42,335	+112%	+$561K	0.58%	31
2016 Q2	$524K	Sell	37,665 -7,335	-16%	-$108K	0.51%	33
2016 Q1	$683K	Sell	45,000 -15,000	-25%	-$229K	0.53%	40
2015 Q4	$1.14M	Buy	+60,000	New	+$1.15M	0.75%	37

Other funds holding PRTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

APCM

Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Opus Point Partners Management's PRTK Position: Q4 2018 in Review

Opus Point Partners Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2018, closing a stake of 18,000 shares — an estimated $175K sold.

Opus Point Partners Management first reported a position in PRTK in Q4 2015 and held it in 12 quarters. The position peaked at $1.54M in Q1 2017. 102 funds tracked by Wall St. Rank hold PRTK as of Q4 2018.

Opus Point Partners Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Opus Point Partners Management sold 18,000 Paratek Pharmaceuticals, Inc. shares in Q4 2018, an estimated $175K.
Opus Point Partners Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2015 and held it in 12 quarters.
Opus Point Partners Management's Paratek Pharmaceuticals, Inc. position peaked at $1.54M in Q1 2017.
102 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2018.

Based on Opus Point Partners Management's 13F filing for Q4 2018, filed 14 Feb 2019.